Tech Company Financing Transactions
Checkmate Pharmaceuticals Funding Round
On 6/17/2017, Checkmate Pharmaceuticals announced $27 million in Series B funding from F-Prime Capital, Sofinnova Ventures and venBio.
Transaction Overview
Company Name
Announced On
6/17/2017
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to further advance clinical development of CMP-001, a first-in-class CpG-A oligonucleotide that activates the innate immune system via Toll-like receptor 9 (TLR9), and which is currently being studied in a Phase 1b trial in combination with pembrolizumab in primary refractory melanoma patients who have either progressed on or failed to respond to anti-PD-1 therapy.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Checkmate Pharma is developing a new approach for cancer immunotherapy, by specifically activating the immune system to recognize and kill tumor cells throughout the body, without harming normal tissues.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/17/2017: Atrium LTS venture capital transaction
Next: 6/17/2017: Guazi.com venture capital transaction
Share this article
News on VC Transactions
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs